

Docket No. ORT-1395

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : J. Guy Breitenbucher et al.

Serial No. : 09/821,244

Art Unit:

Filed : March 29, 2001

Examiner:

For : PHENYL-SUBSTITUTED IMIDAZOPYRIDINES

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

12/3/03
(Date of Deposit)

John W. Harbour
(Name of applicant, assignee, or Registered Representative)


(Signature)

12/3/03
(Date of Signature)

Commissioner for Patents
P.O. Box 1450
Washington, D.C. 20231

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on June 4, 2002.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a) (2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

☐ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:


☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.


Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT-1395/JWH. This form is submitted in triplicate.

Respectfully submitted,



John W. Harbour
Reg. No. 31,365
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2169
DATED: 12/3/03



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | |
|--|-------------------------------|---------------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 2 | Application Number | 09/821,244 |
| | Filing Date | March 29, 2001 |
| | First Named Inventor | J.G. Breitenbucher et al. |
| | Group Art Unit | 1625 |
| | Examiner Name | B.I. Dentz |
| | Attorney Docket Number | ORT-1395 |

U.S. PATENT DOCUMENTS

| Examiner Initials | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document mm-dd-yyyy | Pages, Columns, Lines, where relevant passages or relevant figures appear |
|----------------------|--------------------------|----------------------|--------------------------------------|--|--|---|
| | | Number | Kind Code ² (if known) | | | |
| | | 4,727,145 | A | Press | 02-1988 | |
| | | 4,833,149 | A | Press | 05-1989 | |
| | | 4,861,897 | A | Press et al. | 08-1989 | |
| | | 5,182,291 | A | Gubin et al. | 01-1993 | |
| | | 5,352,707 | A | Pompni et al. | 10-1994 | |
| | | 5,385,912 | A | Neuenschwander et al. | 01-1995 | |
| | | 5,681,954 | A | Yamamoto et al. | 10-1997 | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS


| Examiner Initials | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document mm-dd-yyyy | Pages, Columns, Lines, where relevant passages or relevant figures appear | T ⁶ |
|----------------------|--------------------------|-------------------------|---------------------|-----------------------|--|--|--|----------------|
| | | Office ³ | Number ⁴ | KindCode ⁵ | | | | |
| / | | EP | 0 289 371 | A1 | Synthelabo | 11-1988 | | |
| / | | EP | 0 978 512 | A1 | Societe Civile Bioprojet | 02-2000 | | |
| / | | JP | 52 113992 | A1 | Janssen Pharmaceutica N.V. | 09-1997 | | |
| / | | WO | 97/43271 | A1 | Warner-Lambert Company | 11-1997 | | |
| / | | WO | 98/06703 | A1 | Eli Lilly and Company | 11-1998 | | |
| / | | WO | 98/48797 | A1 | Eli Lilly and Company | 11-1998 | | |
| | | WO | 99/32115 | A1 | Advanced Research and Technology Institute, Inc. et al. | 07-1999 | | |
| | | WO | 99/33822 | A1 | SmithK-Line Beecham Laboratories Pharmaceutiques et al. | 07-1999 | | |
| | | WO | 01/10050 | A1 | Rohde & Schwarz GmbH & Co. KG | 01-2002 | | |
| / | | WO | 01/74815 | A2 | Ortho McNeil Pharmaceutical, Inc. | 10-2001 | | |
| | | | | | | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | |
|--|-------------------------------|---------------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 2 of 2 | Application Number | 09/821,244 |
| | Filing Date | March 29, 2001 |
| | First Named Inventor | J.G. Breitenbucher et al. |
| | Group Art Unit | 1625 |
| | Examiner Name | B.I. Dentz |
| | Attorney Docket Number | ORT-1395 |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| / | | AGARWAL, Shiv K. et al., "Synthesis and pharmacological activities of 1-(2,4-disubstituted phenoxy)-3-[N1-N4-arylpiperazinyl]propanes and 1-(4-chlorobenzoyl)-3-substituted 6-methoxy-2-aryl-3-N1-(N4-phenylpiperazinyl)propoxyphenylindoles", Indian J. Chem., Sect. B (1991), 30B(4), 413-16 | |
| / | | JOSHI, Krishna C. et al., "Preparation of new fluorine containing 2-phenylindole derivatives as antifertility agents", J. Indian Chem. Soc. (1985), 62(5), 388-90 | |
| / | | TAKEUCHI, K. et al., "1,2-disubstituted indole, azaindole and benzimidazole derivatives possessign amine moiety: a novel series of thrombin inhibitors" Bioorg. Med. Chem. Lett. (2000), 10(20), 2347-2351 | |
| / | | WALCZYNSKI, Krzysztof et al., "Non-imidazole histamine H3 ligands, part 2: New 2-substituted benzothiazoles as histamine H3 antagonists", Archiv de Pharmazie, Vol. 332, No. 11, November 1999, pp. 389-398 | |
| / | | WALCZYNSKI, Krzysztof et al., "Non-imidazole histamine H3 ligands. Part I. Synthesis of 2-(1-Piperazinyl)- and 2-(hexahydro-1H, 4-diazepin-1-yl) benzothiazole derivatives as H3-antagonists with H1 blocking activities", Biosciences Information Services, Farmco, Vol. 54, No. 10, October 30, 1999, pp. 684-694 | |
| | | | |
| | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.